How Do You Know If You Need a Colectomy?

If you have ulcerative colitis, you will rarely know you need a colectomy from one symptom. Guidelines recommend removing the colon by one of three routes. The first is an emergency: a severe attack that has not responded to intravenous steroids and then rescue medicine within about a week, or a complication such as a perforation, toxic megacolon or life-threatening bleeding. The second is colitis that stays active despite optimal medical treatment, including being unable to get off steroids or being unable to tolerate the medicines. The third is cancer risk: dysplasia that cannot be removed through the colonoscope, multifocal or invisible dysplasia, a cancer, or some strictures. Outside an emergency, the decision is shared, your preferences count, and asking for a surgical opinion is not the same as agreeing to an operation.

That is the clinical-threshold version of the question. The emotional side of facing the operation, the choice between a pouch and a bag, and what life is like afterwards each have their own article on this site, and we link to them as we go rather than repeating them. This one is about the decision point itself: what has to have happened, what has to have failed, and what the evidence says about timing.

The three routes to a colectomy

Every colectomy for ulcerative colitis starts from one of three situations, and they differ in speed, in how much choice you have, and in which operation is done first. It helps to know which one you are in, because the question "do I need surgery?" means something different in each.

The British Society of Gastroenterology (BSG) guideline sets out the emergency indications as disease that is medically resistant, intolerable medicine side effects, life-threatening haemorrhage, toxic megacolon or perforation, and separately recommends that removal of the colon and rectum "should be offered to patients who have chronic active symptoms despite optimal medical therapy" (Lamb 2019). The cancer route comes from the dysplasia statements covered further down.

The European guideline body, ECCO, published an updated surgical guideline for ulcerative colitis in 2026 (Adamina 2026). Its abstract describes it as covering surgery for medically refractory UC, perioperative optimisation, surgical technique and centre expertise. We could not obtain its full text, so we cite it only for its existence and do not report what it recommends. The BSG guideline, which we read in full, is the main source for the thresholds below.

Route one: when it is an emergency

An emergency colectomy happens during an acute severe attack, either because the medicines have not worked within a short, defined window or because a complication has developed. It is the one route where the decision is mostly made for you, and it is made fast.

The BSG's Statement 20 recommends that people with acute severe ulcerative colitis "who have not responded within 7 days of rescue therapy with infliximab or ciclosporin, or those with a deterioration or complications before that time (including toxic megacolon, severe haemorrhage or perforation) require subtotal colectomy and ileostomy, with preservation of the rectum." It was a strong recommendation with 97.4% agreement, but the guideline rates the underlying evidence as very low quality, which is common for decisions nobody can randomise (Lamb 2019).

What happens before that point, the admission, the intravenous steroids and the formal reassessment on day three, is covered in our guides to when to go to hospital for a UC flare and how long a UC flare lasts, including the Oxford day-three criteria and the trial that compared the two rescue drugs. We are not going to rebuild that here. The part that belongs to this article is why the guideline is so insistent about not letting the clock run on.

Why surgeons worry about waiting too long

Three studies, from England and the US, found that the longer medical treatment continued before an urgent colectomy, the worse people did after it. None of them was a trial, so they cannot prove the delay caused the harm, but they point the same way.

• An Oxford surgical series of 80 people who had urgent colectomy for acute severe colitis between 1994 and 2000 followed them for a median of 5.4 years. Sixty per cent had at least one complication over that time. Those who had a major complication had been on medical treatment longer before surgery: a median of 8 days against 5 days (Randall 2010).
• A US series of 107 people who had colectomy for fulminant colitis found that the duration of preoperative medical treatment was the only significant predictor of postoperative complications in the multivariable analysis (Coakley 2013). Encouragingly, having a complication did not stop people later getting a pouch: 68% and 77% of the two groups eventually did, a difference that was not significant.
• A US national database study of 7,108 colectomies for ulcerative colitis found that among people admitted as emergencies, having surgery 6 days after admission rather than earlier was associated with a higher likelihood of dying in hospital, an adjusted odds ratio of 2.12 (95% CI 1.13 to 3.97). Overall postoperative mortality was 2.3%. Emergency admission itself carried an adjusted odds ratio for death of 5.40, and most operations were done in low-volume hospitals, which had higher mortality (Kaplan 2008).

The BSG draws the practical conclusion directly: timely decision-making matters, a colorectal surgeon and stoma nurse should be involved early, and "surgical input at an early stage helps patients to understand that colectomy is an important treatment option and is not an outcome to be avoided at any cost" (Lamb 2019). In practice, that is why some people meet a surgeon on the ward on day two or three of an admission even though nobody has decided anything yet. Meeting the surgeon is information, not a verdict.

What the emergency operation is, and why the rectum stays

The operation of choice in this setting is a subtotal colectomy with an end ileostomy, leaving the rectum (and sometimes the lower sigmoid colon) in place. The BSG says it can be done laparoscopically or open depending on local expertise, with laparoscopy likely to mean a shorter stay and fewer infections. Doing the pouch at the same time is avoided because the patient is acutely unwell, often low in albumin and on immunosuppressive medicine. Pouch surgery, if wanted, waits a minimum of 3 months and preferably 6 months, and in a Swedish population cohort the median wait was almost 12 months (Lamb 2019).

That design has a quiet benefit people in the threads often point out: the first operation leaves every later option open. You live with the ileostomy and then decide whether to keep it, with the rectum removed later, or go on to a pouch. What I wish I knew before j pouch surgery covers the staging routes in detail.

Route two: colitis that medicine is not controlling

This is the route most people searching this question are on: months or years of active colitis, a list of medicines that have not held, and a growing sense that something has to change. The BSG wording is "chronic active symptoms despite optimal medical therapy", and each part of that phrase carries weight.

"Chronic active" means persistent, not one bad flare that then settles. "Symptoms" is the guideline's word, but in practice your team will also look at what the lining shows on colonoscopy and at markers such as calprotectin. And "optimal medical therapy" is the phrase that people end up arguing about, because the list of available drugs keeps growing.

Steroid dependence is a threshold in its own right

Being unable to get off steroids is one of the clearest signals that medical treatment is not working well enough, and the BSG defines it precisely. Steroid dependency is generally defined as "an inability to wean below 10 mg of prednisolone or 3 mg of budesonide within 3 months of starting, or disease flare within 3 months of stopping steroids." Steroid-refractory disease is active disease despite up to 1 mg/kg/day of prednisolone for 4 weeks. Steroid excess is two or more courses in a year (Lamb 2019).

Those definitions matter because steroid dependence is common and often missed. In a UK audit of 1,176 outpatients with IBD, 14.9% had steroid dependency or excess, and peer reviewers judged about half of those cases (49.1%) to have been avoidable. Dedicated IBD clinics were associated with less inappropriate steroid excess in UC (Selinger 2017).

The reason guidelines treat this as a threshold rather than a nuisance is the harm of long-term steroids. The BSG recommends that prolonged corticosteroid therapy be minimised with specialist and multidisciplinary input. The evidence on mortality needs reading carefully, though. A US study of Medicare and Medicaid patients compared prolonged steroid use with starting an anti-TNF drug and found a significantly lower death rate on anti-TNF in Crohn's disease, but in ulcerative colitis the difference (23.0 versus 30.9 deaths per 1,000 person-years, odds ratio 0.87, 95% CI 0.63 to 1.22) was not statistically significant (Lewis 2018). So the case against living on steroids in UC rests on infections, bone loss, diabetes and the other well-documented side effects, not on a proven mortality figure. It also compared steroids with a drug, not with surgery.

If you have had more than one steroid course this year, write the dates down. Our guide to what to track in an IBD symptom diary treats steroid courses as data for exactly this reason: they are one of the first things a surgeon or second-opinion gastroenterologist will ask about, and memory compresses them.

Side effects you cannot live with

The BSG's list of indications explicitly includes "intolerable side effects of medication" (Lamb 2019). That is worth saying plainly, because people sometimes assume surgery is only on offer once every drug has stopped working. A medicine that controls the colitis but causes a problem you cannot accept is a legitimate reason to discuss surgery, alongside switching to another medicine.

At what point do they stop trying drugs?

There is no agreed number of failed medicines after which surgery becomes necessary, and any page that gives one is offering an opinion. What the guidelines do say is that surgery should be raised every time a drug fails, and that each successive drug tends to work less well.

The BSG puts it this way: "surgery should always be discussed as an option in patients failing a therapeutic agent, particularly as there is generally a reduction in response to each successive immunosuppressive or biologic drug" (Lamb 2019). Note what that does and does not say. It does not say surgery must follow a set number of failures. It says the conversation should not wait.

The "difficult-to-treat" line

The closest thing to a formal threshold is an international consensus on difficult-to-treat IBD, agreed by 16 participants from 12 countries. They defined it as failure of biologics and advanced small molecules with at least two different mechanisms of action, plus some other situations such as Crohn's disease recurring after two resections (Parigi 2023). The definition was written to standardise research and identify people who need enhanced strategies, not to tell anyone when to have surgery. But it is a useful marker: if you have failed two different drug classes, you are in the group the field itself calls difficult to treat, and a formal surgical opinion alongside the next medicine is reasonable.

How does that group do? In two Italian tertiary centres, 430 of 1,736 people with IBD on advanced therapy (24.8%) met at least one difficult-to-treat criterion, most of them by failing at least two mechanisms. Their rates of symptomatic, biochemical and endoscopic remission were all lower than in other patients, most strikingly for endoscopic remission, 25% against 62%. And drug persistence fell progressively with each line of treatment in both Crohn's and UC (Parigi 2025). These were referral centres, which concentrate harder cases, so the numbers are not a forecast for everyone.

Smaller studies fill in the picture without changing it. A meta-analysis of switching to a second anti-TNF drug found only eight ulcerative colitis studies; the six that reported remission gave figures from 0% to 50%, too scattered to pool into anything useful. In Crohn's disease, where there was more data, the chance of remission depended heavily on why the first drug was stopped: 61% if it was stopped for intolerance, 45% after a loss of response, and 30% if it never worked (Gisbert 2015). A French single-centre study of 82 people on a fourth or fifth advanced therapy found drug persistence was greater in Crohn's disease than in UC (Caron 2024).

The r/UlcerativeColitis thread from a 22-year-old weighing vedolizumab, upadacitinib or surgery after tofacitinib, infliximab and ustekinumab had all failed captures the tension well (thread). The most upvoted replies described trying a JAK inhibitor after several biologics and reaching remission. Others warned that "try everything first" can mean years lost to symptoms and steroids. One commenter who had failed nine drugs over six years said they had opted for surgery. Both camps were describing real outcomes; neither was describing a rule.

Another drug or surgery: what each option costs

The fair comparison is not "a drug that might work" against "a big operation", but the realistic cost of each path over the next year. A few pieces of evidence help make that concrete.

• Time on steroids before surgery has a price. A meta-analysis of observational studies found people with IBD who were on steroids at the time of abdominal surgery had more postoperative complications overall (odds ratio 1.41, 95% CI 1.07 to 1.87) and more infectious complications (odds ratio 1.68, 95% CI 1.24 to 2.28), with a higher risk at doses above 40 mg (Subramanian 2008). So a long steroid bridge while waiting to see if another drug works is not free if surgery follows anyway.
• Being on an anti-TNF drug before surgery did not raise infection risk in the largest prospective study. Among 947 people with IBD having intra-abdominal surgery at 17 US sites, infection rates were 18.1% with recent anti-TNF exposure and 20.2% without, and anti-TNF exposure was not associated with infection after adjustment (Cohen 2022). Its grant record lists the Crohn's & Colitis Foundation alongside several drug companies, including Janssen and Pfizer.
• Planned surgery carries less risk than emergency surgery. English hospital data showed three-year mortality of 3.7% after elective colectomy for UC, against 13.6% for people admitted without colectomy and 13.2% after emergency colectomy. The authors concluded that in England "the clinical threshold for elective colectomy in people with inflammatory bowel disease may be too high" (Roberts 2007). This was observational: people well enough for planned surgery differ from those who end up having it as an emergency. Life after colectomy for ulcerative colitis covers these mortality studies and their limits in more detail.

None of that says surgery is the better choice for any one person. It says the option of "one more drug" has a cost in time, steroids and the chance of ending up in the emergency route anyway, and that cost belongs in the comparison.

Why patients and doctors weigh it differently

People with UC, when asked to trade risks, will accept surprisingly large risks from medicines to avoid a permanent stoma, but they see a j pouch very differently from a bag. That finding goes some way to explaining why surgery conversations so often feel tense.

A discrete-choice experiment asked 293 people with UC to choose between medical and surgical options with different features. To avoid an ostomy, participants were willing to accept more than a 5% risk of dying from lymphoma or infection over ten years from medical therapy, regardless of how well the medicine worked. But they viewed j pouch surgery as roughly equivalent to medical treatment that was only partly effective (Bewtra 2014). The study was funded by the Crohn's & Colitis Foundation and the US National Institutes of Health, according to its grant record.

Two things follow. First, much of the fear of colectomy is really fear of a permanent bag, and for many people a permanent bag is not the only outcome on offer (see the section on avoiding a bag below). Second, people differ a great deal in how they weigh these trade-offs, which is why guidelines keep returning to shared decision-making. Surgeons in the threads, and the gastroenterologist quoted in one, describe surgery as "an alternative treatment, not a last resort" (thread). Other commenters had the opposite experience and were told surgery was off the table until every drug had been tried. Both are positions clinicians take; you are entitled to understand which one your team holds and why.

Route three: dysplasia, cancer and strictures

Dysplasia, the precancerous change that surveillance colonoscopy looks for, does not automatically mean colectomy. Whether it does depends on whether it can be seen, whether it can be completely removed, and how many places it appears. This route can apply even when the colitis itself feels well controlled, which is what makes it so disorienting.

The SCENIC international consensus (Laine 2015) set the modern rules, and the BSG reproduces its management statements. We read them in that reproduced form. In summary (Lamb 2019):

• Visible, raised (polypoid) dysplasia that is completely removed: surveillance colonoscopy is recommended rather than colectomy.
• Visible, flat (non-polypoid) dysplasia that is completely removed: surveillance is suggested rather than colectomy.
• Dysplasia that cannot be seen on the scope (invisible), confirmed by a GI pathologist: referral to an endoscopist with expertise in IBD surveillance using high-definition chromoendoscopy.
• Dysplasia that cannot be completely removed because of its extent or number: referral to the multidisciplinary team to discuss definitive management, including surgery.

So the honest answer to "I have dysplasia, do I need a colectomy?" is often "not necessarily, but you need the right people to look." Note that most of those recommendations are graded very low quality evidence, which reflects how hard this is to study rather than that the advice is careless.

How likely is low-grade dysplasia to become cancer?

In a meta-analysis of people with UC and low-grade dysplasia under surveillance, cancer developed at about 0.8% a year, and certain features roughly doubled to tripled the risk of progression. Across 14 surveillance cohorts with 671 people, the pooled annual incidence of colorectal cancer was 0.8% (95% CI 0.4 to 1.3), and of advanced neoplasia (cancer or high-grade dysplasia) 1.8%. Progression was more likely with primary sclerosing cholangitis (odds ratio 3.4), invisible rather than visible dysplasia (1.9), distal rather than proximal location (2.0), and multifocal rather than single-site dysplasia (3.5) (Fumery 2017).

Two details from that paper matter to anyone given this diagnosis:

• Who read the slide changes the number. The annual cancer risk was 1.5% when the dysplasia was diagnosed by an expert gastrointestinal pathologist and 0.2% when diagnosed by community pathologists. That likely reflects how reliably dysplasia is identified, and it is why guidelines insist dysplasia be confirmed by an expert before decisions are made.
• Some people having surgery already had cancer. In 12 surgical cohorts of 450 people who had colectomy for low-grade dysplasia, cancer was found in the removed colon in 34.

The background cancer risk is worth knowing too. The BSG cites cumulative incidence of IBD-associated colorectal cancer of about 1% at 10 years, 3% at 20 years and 7% at 30 years, and recommends a screening colonoscopy 8 years after symptom onset for anyone with colonic disease to set the surveillance schedule (Lamb 2019).

Strictures in ulcerative colitis

A narrowing of the colon is unusual in ulcerative colitis, and when one appears, it raises the question of cancer in a way that it does not in Crohn's disease. In a US hospital series covering 1959 to 1983, 59 of 1,156 people with UC (5%) developed 70 colorectal strictures, and 17 of the 70 (24%) turned out to be malignant. Three features pointed towards cancer: appearing after 20 years of colitis (61% probability of malignancy, against 0% for strictures appearing in the first 10 years), sitting before the splenic flexure (86%), and causing symptomatic bowel obstruction (100%) (Gumaste 1992). The data are old and from one centre, but they explain why a stricture in long-standing UC is usually treated as a reason for surgical discussion rather than watched.

One r/UlcerativeColitis commenter described exactly this: a colon that was narrowing, mounting pain as food struggled to pass, and surgery that moved from "eventually" to "now" (thread).

"Can't they just take out the part with the cancer?"

That was the question in an r/IBD thread from someone with long-standing UC facing surgery for a sigmoid cancer the next day, weighing a full proctocolectomy with a pouch against removing only the affected segment and relying on close surveillance (thread). It is a real dilemma, and the evidence leans one way without being conclusive.

A Japanese multicentre study of 801 people with UC-associated neoplasia across 43 institutions found five-year disease-free survival of 87.8% after total proctocolectomy and 83.9% after subtotal colectomy, against 72.0% after segmental colectomy. Extended surgery had significantly better overall and disease-free survival in the multivariable analysis, while for sporadic cancers in people with UC the operation type made no significant difference (Seishima 2025). A 2025 meta-analysis of eight retrospective studies (4,856 patients) found no statistically significant difference between segmental colectomy and total proctocolectomy, but rated the evidence low quality, warned that the two could not be called equivalent, and noted a suggestion of more later neoplasia and worse survival after segmental surgery. People having segmental surgery in those studies were older and had more other illnesses (Lincango 2025).

So segmental surgery is mostly a compromise for people who cannot safely have the bigger operation, not a like-for-like alternative. Neither study was randomised.

How common is colectomy now?

Much less common than older figures suggest. A Finnish national study of 32,108 people newly diagnosed with UC between 2000 and 2020 found a cumulative colectomy risk of 1.0% at one year, 4.7% at five years and 7.3% at ten years. The risk fell over time: the 5-year risk was about 30% lower for people diagnosed from 2013 onwards than for those diagnosed before biologics were widely used (incidence rate ratio 0.70). Men and people diagnosed in childhood had higher risk, and the risk for older people did not fall (Kontola 2025).

Put another way: the large majority of people diagnosed with UC today will never need a colectomy, and "my colitis is bad" on its own does not predict that you will. Severe attacks needing admission change the picture considerably, and our hospital guide covers what proportion of those end in surgery.

Is the diagnosis certain? Ask before anything irreversible

Before planned surgery for "ulcerative colitis", it is worth confirming that the diagnosis really is ulcerative colitis, because the operation that suits UC does not always suit Crohn's disease. The BSG notes that in 5 to 15% of people with IBD, endoscopy and biopsies cannot distinguish Crohn's colitis from UC, a label called IBD-unclassified, and that a small proportion of UC diagnoses are later changed to IBD-unclassified or Crohn's disease (Lamb 2019).

This is not a theoretical worry in the patient communities. An r/UlcerativeColitis post from a parent whose daughter was re-diagnosed with Crohn's days after her colectomy drew 82 comments, many from people with similar stories of a diagnosis changing after surgery, and several from people who said a second opinion had changed their plans in the other direction (thread). Some of the most upvoted replies made the counterpoint: when no medicine is working, surgery may still be the right call even if the label later changes. How often UC is later re-diagnosed as Crohn's after colectomy, and what that means for a pouch, is covered in life after colectomy.

In a planned (non-emergency) decision, it is reasonable to ask whether your biopsies have been reviewed by a pathologist with IBD experience, whether the small bowel has been imaged, and whether anything in your history (perianal disease, for example) points towards Crohn's. Those are questions for your team, not things to decide yourself, but they belong before the operation, not after.

Crohn's disease: a different decision

People with Crohn's disease of the colon also have colectomies, but the decision is about how much to remove as much as whether to operate, because Crohn's can come back elsewhere in the gut. The options are removing a segment, removing most of the colon and joining the small bowel to the rectum (ileorectal anastomosis), or removing the colon and rectum with a permanent ileostomy.

The evidence is old and observational. A 2006 meta-analysis of six studies (488 patients) found no significant difference in recurrence between segmental colectomy and colectomy with ileorectal anastomosis, but recurrence came 4.4 years later on average after the bigger operation, with a trend favouring it when two or more segments were involved (Tekkis 2006). A 2017 review of 11 studies (1,436 patients) found removing the colon and rectum gave a lower recurrence risk than subtotal colectomy, while segmental colectomy carried a lower risk of a permanent stoma (Angriman 2017). Both concluded that the extent of disease drives the choice.

If you have Crohn's, the medical side of "when" follows the same logic as UC (complications, refractory disease, dysplasia), but the definition of difficult-to-treat disease also includes Crohn's recurring after two resections (Parigi 2023). Our guide to telling whether you are in a Crohn's flare covers the obstructive and stricturing presentations that most often lead to surgery.

Can you have your colon removed and not have a bag?

Often yes, in the end, though most routes involve living with a stoma for a while. For ulcerative colitis there are three main end points after the colon comes out:

• An ileal pouch (j pouch) made from the small bowel and joined to the anus, so stool passes the usual way. It is usually built in two or three stages with a temporary loop ileostomy.
• An ileorectal anastomosis, where the small bowel is joined to a retained rectum. The BSG says it may be preferable in selected women without proctitis because it does not impair fertility, but it is not suitable for everyone and the rectum keeps its cancer risk, so it needs surveillance (Lamb 2019).
• A permanent end ileostomy, with the rectum removed.

The BSG's Statement 21 says pouch reconstruction and end ileostomy "provide equivalently good quality of life, and are a matter of patient choice", and Statement 22 suggests pouch surgery be done in specialist high-volume centres, citing UK data in which high-volume centres had a pouch failure rate of 5.2% (Lamb 2019). The full comparison, including complication rates on each side and why the studies cannot pick a winner, is in j pouch vs ostomy. What everyday life with a stoma involves is covered in how to track food triggers with an ostomy, which also explains how an ileostomy differs from a colostomy and a pouch.

One point that came up in the first thread we read: a woman who had been told a pouch might affect her fertility assumed this ruled it out. Fertility after pelvic surgery is a real issue, and it is a reason to discuss timing and operation type before surgery, not necessarily a reason to rule anything out (thread). Planning pregnancy with ulcerative colitis covers surgery and fertility in detail.

A worked example: three people, three routes

These are illustrative composites, not real patients, built to show how the same question has different answers.

Person A, 31, admitted with a severe flare. Twelve bloody stools a day, a fast pulse and low albumin. Intravenous steroids for three days bring only partial improvement, so rescue infliximab is started and a colorectal surgeon visits. Five days later there is little change, and the team recommends a subtotal colectomy. For Person A, the question was never really "do I need one?" but "how long do we wait?", and the evidence says not long. The rectum is left; the pouch decision waits months.

Person B, 26, five years of active pancolitis. Mesalazine, azathioprine, two biologics and a JAK inhibitor have each failed or stopped working, and there have been three steroid courses in the last year. She has met the BSG definition of steroid dependence and the consensus definition of difficult-to-treat disease. Nothing is an emergency. Her gastroenterologist offers a further biologic from a class she has not tried; she also asks for a surgical opinion. Both are reasonable. What helps her decide is writing down the next drug's realistic chance, how long she would give it, what she would do if it failed, and what she would want from surgery if she chose it.

Person C, 58, UC for 25 years, well controlled. A surveillance colonoscopy finds a small raised area of low-grade dysplasia, which is completely removed. He assumed this meant losing his colon. Under the SCENIC statements, completely removed visible dysplasia leads to closer surveillance, not colectomy. If a later scope found dysplasia that could not be removed, or dysplasia in several places, the conversation would change.

What to track if surgery is being discussed

The most useful record at this stage is not a daily symptom log but a treatment history: every drug, when it started, when it stopped, and why. "Why it stopped" matters because the reason a drug failed changes the odds for the next one (Gisbert 2015). Worth having on one page:

• Each medicine, its start and stop dates, and whether it never worked, stopped working, or caused side effects.
• Every steroid course, with dates and starting dose, so steroid dependence or excess is visible at a glance.
• Hospital admissions and their dates.
• Your typical stool frequency, bleeding and night-time trips on a normal week and on a bad week.
• Recent blood results (haemoglobin, albumin, CRP) and calprotectin, if you have them.
• Any dysplasia results, with the date and whether it was removed.

Our guide to a symptom tracker for your doctor covers how to hand this over so it actually gets read. If you use Clairop, it calculates the PRO-2 score for ulcerative colitis from what you log and produces a one-page summary with score trend, days with blood, overnight episodes and medication adherence, which is the kind of trend a surgical conversation benefits from. It does not decide anything about surgery.

The questions that actually move the decision

The general list of what to ask a gastroenterologist about colitis lives in our colitis questions guide, and the surgeon questions are in the before j pouch surgery article. These few are specific to whether surgery is needed now:

1. Which route am I on? Emergency, refractory disease, or dysplasia. The answer sets the timescale.
2. What would have to happen for you to recommend surgery? A concrete answer turns a vague future into a plan.
3. What is the realistic chance the next medicine works for me, and how long will we give it? Asking for a review date protects against drifting.
4. Am I steroid dependent by the BSG definition? If yes, that is part of the decision whether anyone says so or not.
5. Can I see a colorectal surgeon now, without committing to anything? Guidelines encourage early surgical input.
6. Is the diagnosis secure enough for the operation being discussed?

How do people know it was the right call?

Most of what is published on this is about life after the operation, which our life after colectomy article covers, including regret and quality of life. What is published about the decision itself is mostly about how poorly people are informed.

A qualitative study interviewed 16 people who had considered surgery for UC: 8 who had it (5 with permanent ileostomies, 3 with pouches) and 8 who declined. The main gaps people described were information about the long-term effects of surgery, the practicalities of daily living and long-term support, and peer support was something people wanted but health professionals rarely offered (Baker 2018). A systematic review by the same group assessed 25 online resources about UC surgery and found them generally poor quality and hard to read, and none compared surgery with continued medical treatment (Baker 2017). Our own search for this article found the same thing: the pages that came up were mostly lists of indications with no thresholds, numbers or sources.

In the threads, the pattern is fairly consistent. People who had surgery after years of refractory disease often say they wish they had done it sooner. People who held out and found a drug that worked are glad they did. People whose diagnosis later changed, or who had complications, are more ambivalent. A post titled "Finally decided to do surgery" captured something many describe: a sense of defeat alongside relief, which the replies reframed firmly as taking control (thread). None of that is evidence about outcomes, but it is an accurate map of the feelings involved.

Myths worth dropping

"Surgery is the last resort." The BSG frames colectomy as a treatment option to be discussed whenever a medicine fails, and lists chronic active disease, steroid dependence and intolerable side effects as reasons to offer it (Lamb 2019). It can be the right choice before every drug has been tried, and it can be the wrong choice after many have failed. It is a decision, not a failure.

"You have to try every drug first." No guideline we read sets a number. The consensus definition of difficult-to-treat disease, failure of two mechanisms of action, is a research definition, not a gate (Parigi 2023).

"Dysplasia means your colon has to come out." Completely removed visible dysplasia is usually managed with surveillance (Lamb 2019).

"A colectomy cures ulcerative colitis." It removes the colon, but primary sclerosing cholangitis and some other conditions outside the gut continue, a pouch can develop pouchitis, and a retained rectum can stay inflamed. Life after colectomy sets out what leaves with the colon and what does not.

"If I go to hospital, they will take my colon." Most people admitted with a UC flare do not have a colectomy, and colectomy rates have fallen (Kontola 2025). Avoiding hospital during a severe flare to avoid surgery is the one choice the evidence on delay argues against most clearly.

"Everyone ends up with a permanent bag." Many people go on to a pouch or, in selected cases, an ileorectal anastomosis. Some choose a permanent ileostomy and are glad they did.

When to see a doctor promptly

Contact your IBD team or get urgent care the same day if you have:

• Six or more bloody stools a day, especially with fever, a fast heart rate, dizziness or feeling faint.
• A swollen, tense or very tender abdomen, or pain that is getting worse rather than better.
• Heavy bleeding, passing clots, or signs of significant blood loss such as breathlessness or a racing heart.
• Being unable to keep fluids down, or signs of dehydration.
• Sudden improvement in stool frequency together with a swollen painful abdomen, which can be a warning sign rather than good news.
• New symptoms of bowel obstruction: vomiting, a swollen abdomen and being unable to pass stool or wind.

Also see a doctor promptly, rather than waiting for your next routine appointment, if you notice unexplained weight loss, a change in symptoms after years of stable colitis, or symptoms that are not responding to a treatment you were told should work by now. And if you are on steroids for more than a few months, or have needed two courses in a year, raise it, because that is a threshold in its own right.

The honest bottom line

You usually find out that you need a colectomy not from a symptom but from a pattern: a severe attack that does not turn, medicines that keep failing or keep you on steroids, or dysplasia that cannot be removed. In an emergency the decision is fast and the evidence says delay is risky. In the other two routes you have time, and you have a say.

The most useful things you can do are to know which route you are on, to ask for a surgical opinion early without treating it as a commitment, to keep a clear record of every drug and steroid course, and to make sure the diagnosis is secure before anything irreversible. Guidelines and patients alike increasingly describe surgery as one treatment among several. Whether it is the right one for you depends on numbers your team can give you and on values only you can supply.